Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin‐induced eIF4E activation

Publisher: John Wiley & Sons Inc

E-ISSN: 1099-0461|32|1|jbt.22007-jbt.22007

ISSN: 1095-6670

Source: JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (FORMERLY JOURNAL OF BIOCHEMICAL TOXICOLOGY), Vol.32, Iss.1, 2018-01, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content